Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

被引：0
|
作者：
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
机构：
[1] University of Alabama at Birmingham,
[2] Comprehensive Cancer Center,undefined
[3] Oregon Health & Science University,undefined
[4] University of Texas Southwestern,undefined
[5] Division of Hematology and Oncology,undefined
[6] University of Wisconsin Carbone Cancer Center,undefined
[7] Pfizer Inc,undefined
[8] Global Research and Development,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Sunitinib; Docetaxel; Solid tumors; Phase I; NSCLC; Antiangiogenesis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：669 / 680
页数：11
相关论文
共 50 条
  • [21] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Véronique Diéras
    Thomas Bachelot
    Mario Campone
    Nicolas Isambert
    Florence Joly
    Christophe Le Tourneau
    Philippe Cassier
    Emmanuelle Bompas
    Pierre Fumoleau
    Sabine Noal
    Christine Orsini
    Marta Jimenez
    Diane Charlotte Imbs
    Etienne Chatelut
    Oncology and Therapy, 2016, 4 (2) : 211 - 223
  • [22] Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors
    Bendell, JC
    Eder, JP
    Clark, JW
    Fidias, P
    Lynch, TJ
    Seiden, MV
    Ryan, DP
    CANCER, 2005, 103 (09) : 1925 - 1931
  • [23] A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
    Dieras, Veronique
    Bachelot, Thomas
    Campone, Mario
    Isambert, Nicolas
    Joly, Florence
    Le Tourneau, Christophe
    Cassier, Philippe
    Bompas, Emmanuelle
    Fumoleau, Pierre
    Noal, Sabine
    Orsini, Christine
    Jimenez, Marta
    Imbs, Diane Charlotte
    Chatelut, Etienne
    ONCOLOGY AND THERAPY, 2016, 4 (02) : 211 - 223
  • [24] A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors
    Sweeney, C.
    Verschraegen, C.
    Chiorean, G.
    Lee, F.
    Jones, S.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Awada, Ahmad
    Matos-Pita, Arturo S.
    Aftimos, Philippe
    Bahleda, Ratislav
    Varga, Andrea
    Soria, Jean-Charles
    ANTI-CANCER DRUGS, 2016, 27 (10) : 1021 - 1027
  • [26] Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors
    Masters, GA
    Brockstein, BE
    Mani, S
    Ratain, MJ
    MEDICAL ONCOLOGY, 2003, 20 (01) : 7 - 12
  • [27] Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors
    Gregory A. Masters
    Bruce E. Brockstein
    Sridhar Mani
    Mark J. Ratain
    Medical Oncology, 2003, 20 : 7 - 12
  • [28] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
    Sandrine Aspeslagh
    Kunwar Shailubhai
    Rastilav Bahleda
    Anas Gazzah
    Andréa Varga
    Antoine Hollebecque
    Christophe Massard
    Anna Spreafico
    Michele Reni
    Jean-Charles Soria
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1257 - 1265
  • [29] Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors
    Aspeslagh, Sandrine
    Shailubhai, Kunwar
    Bahleda, Rastilav
    Gazzah, Anas
    Varga, Andrea
    Hollebecque, Antoine
    Massard, Christophe
    Spreafico, Anna
    Reni, Michele
    Soria, Jean-Charles
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (06) : 1257 - 1265
  • [30] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
12345